Introduction
Angiogenesis is required for the invasion and metastasis of cancer cells, including melanoma. Integrins are a class of cell surface adhesion molecules essential in endothelial cell proliferation and tumor angiogenesis, and they are widely expressed in tumor-associated endothelial cells [1, 2] . Specifically, integrin a v b 3 binds to extracellular matrix components such as vitronectin, fibronectins, matrix degradation products, and thrombospondins, leading to a decrease in p21, inhibition of p53, and suppression of bax-mediated cell death [3] [4] [5] [6] [7] . Thus, integrin a v b 3 is crucial in the process of neovascularization or angiogenesis.
Consistent with melanoma cells inducing angiogenesis, tumor-associated endothelial cells in melanoma have upregulated a v b 3 [8] , which is essential in endothelial cell proliferation, maturation, and survival. In addition to being expressed in endothelial cells, a v b 3 is expressed in melanoma cells. a v b 3 is expressed in 86% of melanomas during the tumorigenic vertical growth phase and in 96% of metastatic lesions, and it has been suggested that this integrin plays an important role in the metastatic process of melanoma [9] . a v b 3 expression has also been found to be strongly associated with a poor prognosis in patients with melanoma [10, 11] . Therefore, inhibition of integrin a v b 3 may provide a clinical benefit in patients with advanced melanoma through an antivascular effect as well as a possible direct antitumor effect.
All supplementary digital content is available directly from the corresponding author. Cilengitide (EMD 121974) is the inner salt of a cyclic pentapeptide and is a potent and selective integrin inhibitor [12] . It binds most specifically to integrin a v b 3 at a nanomolar range (B2 nmol/l) and integrin a v b 5 to inhibit the binding of this integrin to vitronectin. Preclinical studies have shown that cilengitide blocked cytokine-induced basic fibroblast growth factor (bFGF)mediated and vascular endothelial growth factor (VEGF)mediated angiogenesis in a chorioallantoic membrane model (cilengitide, Investigators Brochure) and inhibited tumor growth in a chick chorioallantoic membrane model, nude mice, and severe combined immunodeficient mice inoculated with human tumor cells, including melanoma cells (cilengitide, Investigators Brochure).
Phase I trials of cilengitide have shown that doses up to 2400 mg/m 2 administered twice weekly were well tolerated, but the maximum-tolerated dose has not been established [13, 14] . In these trials, a maximum concentration equivalent to that found to be active in preclinical studies (11-13 mg/ml) was achieved at a dose as low as 120 mg/m 2 , although this concentration was not sustained for a long time because of a relatively short half-life (B2.3-4.0 h for doses of 120-1200 mg/m 2 ). Complete responses were reported at 360 and 2400 mg/m 2 in patients with recurrent malignant glioma [14] The responses observed at both low and high dose levels suggest that high doses or prolonged exposure of cilengitide may not be necessary for clinical activity.
In light of the previous clinical experience with cilengitide in solid and hematologic tumors, we conducted a randomized phase II trial to assess the clinical benefit of cilengitide at two different doses in patients with advanced melanoma and performed a pharmacokinetic analysis and correlative studies to examine the molecular effects of cilengitide on melanoma and endothelial cells. Because the estimated progression-free survival (PFS) rate at 8 weeks is B40% for dacarbazine [15] , the standard therapy for advanced melanoma at the time of study design, we assume that a PFS rate of at least 65% at 8 weeks would be considered efficacious.
Methods

Patient selection
The protocol for this study was approved by the Institutional Review Board of The University of Texas, MD Anderson Cancer Center. All patients provided written informed consent before enrollment.
Eligible patients were required to have histologically confirmed stage IV or unresectable stage III nonchoroidal melanoma with measurable metastases and to have undergone no more than one previous systemic treatment, not counting adjuvant interferon-a. Patients had to be at least 18 years of age with an Eastern Cooperative Oncology Group performance status of 0-2 and adequate bone marrow, kidney, and liver function. Patients with brain metastases must have had their brain lesions controlled, asymptomatic for at least 3 months after an adequate local treatment. Patients with any history of wound-healing disorders or advanced coronary disease or a recent history (within 6 months) of peptic ulcer disease were excluded.
Treatment plan
This was a double-blind, randomized phase II clinical trial. Upon enrollment, all patients underwent a mandatory core-needle or skin punch biopsy 5-7 days before the first treatment to assess baseline a v b 3 expression by immunohistochemical (IHC) staining. Patients were randomly assigned in a 1 : 1 ratio to receive either 500 or 2000 mg of cilengitide by an intravenous infusion over 1 h twice weekly. Patients were stratified using the Pocock-Simon minimization method [16] by the following factors: previous systemic treatment (no/yes); visceral metastases (no/yes); serum lactate dehydrogenase level (normal/abnormal); and tumor a v b 3 overexpression (no/ yes), where overexpression was defined as more than 25% of melanoma cells expressing this marker.
No intrapatient dose escalation was allowed. Each treatment cycle lasted 4 weeks, with a maximum of six treatment cycles administered.
On day 8 of the first cycle, an optional tumor biopsy was performed within 6 h after the completion of treatment in patients who consented to correlative studies. Because of possible complications with wound healing from the biopsy, treatment was not administered on day 11 of the first cycle.
Response evaluation
Radiologic assessment including computed tomography was performed after every two cycles. Clinical responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) [17] . The overall clinical response included both complete and partial responses. PFS (time to disease progression from the date of treatment initiation) and overall survival (OS; time to death of any cause from the date of treatment initiation) were determined from day 1 of treatment.
Toxicity evaluation
Toxicities were evaluated and recorded according to the National Cancer Institute's Common Toxicity Criteria version 3.0. Complete blood counts and serum chemistry panels were obtained every 2 weeks.
Population pharmacokinetic analysis
Blood samples were drawn into heparin-containing tubes at the following time points: predose and 2, 4, and 24 h after the start of treatment infusion on day 1 of the first and second cycles and predose and 4 h after the start of treatment on day 8 of the first and second cycles.
Phase II trial of cilengitide for melanoma Kim et al. 295 Blood samples were then immediately centrifuged at 1500 rpm for 10 min at 41C for separation. Plasma samples were aliquoted and stored in labeled cryovials at B701C until analysis. Cilengitide concentrations were determined using the validated liquid chromatography-mass spectrometry protocol at Merck KGaA (Darmstadt, Germany). The validated calibration range was 0.2-100 mg/ml.
Because of the limited number of sampling time points, no standard compartmental or noncompartmental data analyses were carried out and only concentration data are presented.
Tumoral a v b 3 expression analyses
Tissue samples were analyzed using IHC staining for integrin a v b 3 (LM 609; Millipore, Billerica, Massachusetts, USA). The stained tissue slides were examined by two pathologists, who reached a consensus for the grade of each sample on the basis of the percentage of cells expressing a v b 3 . The IHC labeling grades were as follows: 0, no positive cells; + 1, 1-10% positive cells; + 2, 11-25% positive cells; + 3, 26-75% positive cells; and + 4, greater than 75% positive cells. For stratification, we defined 0, + 1, and + 2 as negative expression and + 3 and + 4 as positive expression.
Pharmacodynamic studies
To assess the downstream molecular changes within the tumor by cilengitide treatment, the expressions of pERK1/2 [E-4 (sc-7383); Santa Cruz Biotechnology Inc., Santa Cruz, California, USA], pAKT [Phospho-Akt (Ser473) antibody (IHC specific) (9277); Cell Signaling Technology, Danvers, Massachusetts, USA], and pFAK1 [FAK pY861 (44-626G); BioSource, Grand Island, New York, USA] were analyzed by IHC staining using methods identical to those used to determine a v b 3 expression, as described above. The IHC grades were 0, 5% or fewer positive cells; + 1, 6-25% positive cells; + 2, 26-75% positive cells; and + 3, greater than 75% positive cells.
Statistical analysis
This trial implemented Simon's optimal two-stage design [18] , with a proposed sample size of 28 for each dose group. The primary endpoint was the PFS rate at 8 weeks. The assumed null rate was 40% and the target rate was 65% for both dose groups. The design was set with a type I error rate of 10% and a power of 90%. If five or fewer of the first 13 patients in each group were free of disease progression after two treatment cycles, that group would be terminated early because of futility.
Pharmacokinetic data were summarized using mean, standard deviation, and percent coefficient of variation by group. a v b 3 expressions analyzed by IHC staining before and after treatment were compared using the paired t-test. Correlations of changes in a v b 3 expression with changes in other kinases were assessed using Spearman's correlation test. PFS and OS were estimated using the Kaplan-Meier method. Patients whose disease did not progress or who did not die were censored at the last follow-up date. The median PFS and OS and the PFS rate at 8 weeks were estimated and the corresponding 95% confidence intervals (CIs) were provided for the entire group of patients and for each dose group. All analyses were carried out on an intent-to-treat basis. Statistical tests were two-sided and P less than or equal to 0.05 was considered statistically significant. Statistical analysis was carried out using SAS version 9 (SAS Institute, Cary, North Carolina, USA).
Results
Patient characteristics
From August 2004 to March 2006, 29 patients were enrolled and 26 were treated with cilengitide. Two patients withdrew consent before the randomization, and one patient was not eligible to receive the study drug because the baseline tumor biopsy of the supraclavicular lymph node indicated a non-small-cell carcinoma. The pretreatment characteristics of the patients are listed in Table 1 . All 26 treated patients were evaluable for toxicity and 25 patients were evaluable for response.
Treatment
The 26 patients received a total of 56 cycles of cilengitide (median, two cycles per patient; range, <1-6). One patient in the 500 mg dose group was unable to complete the first cycle of therapy because of rapid disease progression. In the 500 mg dose group, one patient received less than one cycle, three received one cycle, eight received two cycles, one received four cycles, and one received six cycles. In the 2000 mg dose group, four patients received one cycle, seven received two cycles, and one received six cycles. None of the patients required dose reductions.
Progression-free survival and responses Table 2 summarizes the PFS and tumor response. Only three patients remained free of disease progression per RECIST at 8 weeks. The PFS durations of these three patients were 10.6, 5.5, and 3.9 months, respectively. A 71-year-old Caucasian woman with melanoma metastases in the lungs and with numerous cutaneous in-transit melanoma lesions in her left lower extremity showed a prolonged partial response after the initial enlargement of her cutaneous lesions while receiving 2000 mg of cilengitide. After one treatment cycle, the sum of the largest diameters of five target lesions on her leg increased by 28%. Although the disease progressed per RECIST, she was allowed to continue treatment under the protocol. After the second cycle, her disease began to regress. She completed six cycles and remained free of disease progression for 5 months afterward until the disease progressed in the lungs. The in-transit lesions in her leg remained stable without progression at the last follow-up evaluation at the 14th month (Fig. 1 ). The best response in the other two patients who were free of disease progression at 8 weeks was stable disease.
The PFS rate at 8 weeks was 12% (95% CI, 4-33%) among all 26 patients and 14% (95% CI, 4-52%) and 8% (95% CI, 1-54%) among the 14 patients at the 500 mg dose and the 12 patients at the 2000 mg dose, respectively. Therefore, the study (both dose groups) was terminated early. The median OS was 9.6 months (95% CI, 5.2-42.5 months), with six patients still alive after more than 4 years. These six patients received various chemotherapy regimens with or without immunotherapy and/or surgical resection. None of the six patients received either vemurafenib or ipiliumumab after their disease progressed on cilengitide.
Toxicity Table 3 lists the adverse events. The only adverse event greater than grade 2 was one case of grade 3 lymphopenia in a patient in the 2000 mg dose group. None of the patients required treatment discontinuation nor dose reduction for toxicity. Although both doses of cilengitide were well tolerated, the 2000 mg dose was associated with higher incidences of grade 2 fatigue, arthralgia, lymphopenia, peripheral neuropathy, and gastrointestinal disorders.
Pharmacokinetic analysis
Plasma samples for the pharmacokinetic analysis were available from eight patients in the 500 mg dose group and from 10 patients in the 2000 mg dose group. Table 4 shows the mean plasma cilengitide concentration by dose group and treatment cycle. No accumulation was observed in either group after repeated biweekly doses. As anticipated, patients treated at the 2000 mg dose level had higher cilengitide exposures than patients treated with 500 mg. Increases in plasma concentrations at the given time points were dose proportional, and the data were consistent with the findings reported in preclinical studies.
Correlative studies
All 26 patients treated in this study underwent tumor biopsy at baseline; 18 underwent a repeat tumor biopsy on day 8. At baseline, six patients (23%) had more than 10% of tumor cells stained positive for a v b 3 , and of these six patients, five patients (19%) had more than 25% of their tumor cells stained positive for a v b 3 ( Table 5 ). One of the biopsies on day 8 did not yield an adequate amount of tumor tissue to analyze for a v b 3 expression; therefore, 17 matching samples were available for analyses of a v b 3 expression. Overall, a v b 3 expression decreased with cilengitide treatment (P = 0.05); among eight patients with matching tumor samples with any detectable level of a v b 3 expression at baseline, a v b 3 expression decreased in five and increased in none. The sole responder and one of the two patients with stable disease had no tumoral a v b 3 expression at baseline. 
Discussion
In this trial, we showed that at a dose up to 2000 mg cilengitide administered intravenously twice weekly is well tolerated, but it does not offer patients with metastatic melanoma significant clinical benefits, despite its ability to decrease tumoral a v b 3 expression. It is interesting that only 42% of the patients showed a v b 3 expression in their tumors in our study, whereas the available literatures report that almost 80-90% of melanomas express a v b 3 . It is not clear whether the different thresholds used in other studies for a v b 3 expression to be labeled positive could explain the discrepancy. Because the tumor of the only responder in our study did not express a v b 3 , we speculate that cilengitide exerts its clinical effect mostly through an angiogenic mechanism rather than by directly targeting melanoma cells, although it is possible that a v b 5 integrin might have been the main target of the anticancer activity in the sole responder. There are several potential explanations for the lack of clinical activity.
The half-life of cilengitide is less than 5 h [13] , and in our study, the pharmacokinetic analysis showed that the plasma concentration of cilengitide was below the biologically active level of 11-13 mg/ml predicted from preclinical studies after 24 h of the drug administration and even after 4 h in the 500 mg dose; therefore, the dosing schedule used in our study might have been suboptimal. The biweekly schedule of cilengitide administration was selected on the basis of limited preclinical studies and also mainly because of the practicality. However, this dosing schedule is likely to be suboptimal, and a more frequent or a continuous infusion schedule may be more appropriate for cilengitide treatment.
Cilengitide has been studied in other cancer types, with variable results. In particular, it appears to have a meaningful clinical benefit in patients with recurrent glioblastoma multiforme. In a randomized phase II study of cilengitide using the same dosing schedules as in our study, the 6-month PFS rate was 15% and the median OS duration was 9.9 months, with a trend toward higher antitumor activity in the 2000 mg dose cohort among Phase II trial of cilengitide for melanoma Kim et al. 299 81 patients with glioblastoma multiforme [19] . On the basis of the results of that trial, it is likely that a higher dose or more frequent doses of cilengitide would lead to superior clinical benefit in patients with advanced melanoma, which appears to be less sensitive to cilengitide treatment.
Another possible explanation for the poor clinical efficacy is that integrins other than a v b 3 confer a resistance to cilengitide treatment. Although a v b 3 appears to be important for the proliferation, survival, and invasion of endothelial cells and the metastasis of melanoma cells, it may not be sufficient to support tumor progression in patients. This conjecture is also suggested by the results of a clinical study of etaracizumab, a specific humanized antibody of integrin a v b 3 , in patients with metastatic melanoma [20] . Among 112 patients who were treated with etaracizumab with or without dacarbazine in a randomized phase II study, none of 57 patients who received etaracizumab alone showed a clinical response and only 12.7% of the patients in the combination arm had a clinical response.
It has been shown that other integrins, such as a 5 b 1 , are also involved in angiogenesis [21] [22] [23] . It is also conceivable that subsets of tumor-associated endothelial cells and melanoma cells may be less dependent on the integrin binding to the extracellular components, but rather more dependent on other proangiogenic growth factors, such as interleukin-8, VEGF, or bFGF, produced by tumor cells. Early evidence has shown that drugs that target VEGF receptors and/or bFGF receptors can be effective in a subset of patients with metastatic melanoma. In a phase II study of axitinib, a potent inhibitor of VEGF receptor-1, -2, and -3, five (16%) of 32 treated patients with advanced melanoma showed an objective clinical response [24] . In a phase I study of E7080, a tyrosine kinase inhibitor of VEGF receptor-1 and -2, bFGF receptor, and platelet-derived growth factor receptor-b, in patients with advanced solid tumors, at least two patients with melanoma showed a confirmed partial response [25] . Successful antivascular therapy might require a multitarget drug or a combination of multiple drugs that inhibit various angiogenic factors together.
Similarly, the clinical efficacy of cilengitide in patients with advanced melanoma may be enhanced by combining with cytotoxic chemotherapeutic drugs. Tentori et al. [26] showed the synergistic antiproliferative effects of the combination of cilengitide and temozolomide against melanoma and endothelial cells in vitro, and the more effective tumor reduction compared with temozolomide alone in vivo. In a phase I/II trial of cilengitide in combination with temozolomide and radiation therapy in patients with glioblastoma, the 6-and 12-month PFS rates were 69 and 33%, respectively, and the median PFS was 8.0 months, suggesting a promising efficacy of this combined modality [27] . These preclinical and clinical findings suggest that the combination of cilengitide with temozolomide may provide superior clinical benefit than either drug alone.
It is interesting to note that the patient who achieved a partial response in our study had an initial tumor enlargement after 4 weeks of treatment. This phenomenon of late tumor regression has been found in animal models after treatment with antivascular drugs, such as angiostatin. This result suggests that clinical studies of antivascular drugs should not mandate that treatment be discontinued in patients who have an initial disease enlargement as per RECIST. Accordingly, the conventionally accepted methods, such as RECIST or WHO criteria, in cancer therapy trials may not provide the most accurate assessment of the drug effect, especially antiangiogenic drugs. Perhaps, other imaging modalities measuring the metabolic or the tumor vascular flow activity of tumor lesions, such as 18 F-FDG-PET or dynamic contrast MRI scans, may be more appropriate for the evaluation of antiangiogenic agents. The investigation of these imaging modalities in current clinical trials of various antiangiogenic drugs may provide an answer to these questions.
In conclusion, single-agent cilengitide administered at a dose up to 2000 mg twice weekly has minimal clinical The first number is an indicator of the percentage of cells staining positively for a v b 3 expression (0, 0%; 1 + , 1-10%; 2 + , 11-25%; 3 + , 26-75%; 4 + , 76-100%); the second number denotes the staining intensity (1, weak; 2, moderate; 3, strong). NA, not adequate (amount of tumor for analysis); NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease; -, no tissue available for analysis. efficacy in patients with metastatic melanoma. A prolonged, continuous infusion schedule and the combination of cilengitide with other targeted drugs should be considered to further develop cilengitide as a treatment for advanced melanoma.
